| INTRODUC TI ON
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV).
According to the Global Hepatitis Report (WHO, 2017), approximately 71 million people worldwide have chronic HCV infection and 399 000 people die each year from hepatitis C, mostly from cirrhosis or hepatocellular carcinoma.
1
Although direct-acting antiviral treatment for HCV is becoming simpler and more effective, HCV infection is asymptomatic in the majority of patients; thus, it remains difficult to diagnose clinically until more advanced stages of fibrosis are present. 2, 3 HCV infection diagnosis relies heavily on clinical laboratory tests, including anti-HCV antibody detection, detection of HCV core antigen (HCVcAg), and nucleic acid testing (NAT) for HCV RNA. 4, 5 In clinical practice, HCV infection diagnosis is a two-step process that starts with an anti-HCV assay, which is typically used to screen for virus exposure, followed by the more complex and expensive NAT to confirm viremia.
Chemiluminescent immunoassays (CLIAs) for anti-HCV antibody detection have been fully automated using high-throughput, random access instruments that are widely used as a screening tool for HCV infection, particularly in high-volume clinical laboratories. Recently, the new Mindray anti-HCV assay was developed for clinical laboratories.
It is a third-generation immunoassay using antigens corresponding to the HCV core, NS3, and NS4 proteins for the qualitative detection of anti-HCV antibodies in human serum or plasma. The aim of this study was to evaluate its clinical diagnostic performance compared with that of the Architect anti-HCV assay and Elecsys anti-HCV II assay.
| MATERIAL S AND ME THODS

| Subjects
This study included a total of 1952 cases from Peking University
People's Hospital. The median patient age was 58 years (range, 5 to 89 years), and 894 and 1058 patients were male and female, respectively. This study was approved by the ethics committee of Peking University People's Hospital.
| Serological assays for HCV antibody detection
This prospective study was conducted in two stages. In the first stage, 1860 consecutive unselected fresh serum samples, which were submitted daily to the Department of Clinical Laboratory of Peking University
People's Hospital for routine clinical testing, were analyzed using the Architect anti-HCV assay on the Architect i2000 system (Abbott Diagnostics, Wiesbaden, Germany). These samples were collected from The results from all three anti-HCV assays are expressed as signal-to-cut-off (S/CO) ratios, with a S/CO ratio of < 1.0 indicating a nonreactive result and a S/CO ratio of ≥ 1.0 indicating a reactive result. The tested samples that were initially reactive were retested in duplicate. If one or both duplicates were reactive, the result was considered anti-HCV antibody CLIA-reactive, and S/CO levels corresponded to the antibody concentration. Table 1 .
| Seroconversion panels
Six HCV infection seroconversion panels were used to evaluate the sensitivity of the Mindray anti-HCV assay and Elecsys anti-HCV II assays for early detection. These panels included PHV913, PHV915, PHV917, PHV920, PHV922, and PHV925 (Sera-Care Life Sciences, Milford, MA, USA).
| Statistical analysis
Statistical analysis was carried out using SPSS statistical software ver- 
| RE SULTS
| Sensitivity of the assays for the early detection of HCV infection
Six HCV infection seroconversion panels were used, and the Mindray anti-HCV assay detected seroconversion in an average of 12.5 days (7, 12, 85, 13, 7, and 27 days), while the Elecsys anti-HCV II assay
detected seroconversion in average of 10.5 days (7, 5, 85, 13, 14, and 8 days) ( Figure 2 ). There was no significant difference between the two assays (P = .818).
| Serological assays for HCV antibody detection
Of the 1952 enrolled samples, 1771 samples subjected to CLIAs were nonreactive in all three assays. These cases indicated no HCV infec- 
| Diagnostic performance of the three anti-HCV assays
The sensitivity, specificity, PPV, NPV, LR+ and LR-of each assay for the detection of HCV infection are listed in Table 2 as follows: the Table 3 and Table 4 .
There were no significant differences in the sensitivity, NPV and LRamong the three assays (P > .05). There were significant differences in the specificity, PPV, and LR+ between the two assays (P < .001).
| S/CO ratio analysis of the three anti-HCV assays
For the 181 samples with at least one anti-HCV CLIA-reactive result, the scatter diagrams of the S/CO ratios for each anti-HCV assay are shown in Figure 3 . There was a good correlation between the Mindray anti-HCV assay and Architect anti-HCV assay (r = .916, P < .001; Figure 3A ). However, we found a significant but weak positive correlation between the Mindray anti-HCV assay and the Elecsys anti-HCV II assay (r = .364, P < .001; Figure 3B ) and between the Elecsys anti-HCV II assay and the Architect assay (r = .430, P < .001; Figure 3C ). The distribution of the S/CO ratios for the 181 samples associated with each anti-HCV assay is shown in Figure 4 . spectively. There were significant differences in the distribution of the S/CO ratios between each pair of assays (P < .001). 
F I G U R E 2 Results of the six HCV seroconversion panels using two different anti-HCV assays
TA B L E 2 Diagnostic performance of anti-HCV assays for the detection of HCV infection (n = 1952)
Assay and results
HCV infection
| D ISCUSS I ON
Early detection of HCV antibody is important for the effective screening and fast diagnosis of HCV infection, enabling infected patients to be diagnosed and treated to prevent disease progression and viral spread. Previous studies have revealed that the Elecsys anti-HCV II assay is more sensitive for early detection than the Architect anti-HCV assay and other comparative assays. 6, 7 According to our study, the Mindray anti-HCV assay displayed a similar sensitivity to the Elecsys anti-HCV II assay with respect to the early detection of HCV infection.
Screening tests for the diagnosis of infectious diseases need to
have high sensitivities to detect all or nearly all affected individuals.
Consequently, screening tests generally produce more false-positive results and require good available supplemental tests. RIBA is laborintensive and time-consuming and is no longer recommended as a supplemental test for anti-HCV confirmation in the 2013 CDC guidelines, and only NAT is required. 8 RIBA is still commonly used due to its high specificity in other countries, including China. 9 In the present study, from 61.0% to 100% and the specificity being high, ranging from 97.5% to 100%. 6, 7, [12] [13] [14] In the present study, we evaluated the diag- These results are consistent with those of several previous studies in which the diagnostic performance of the Elecsys anti-HCV II assay was compared with that of the Architect anti-HCV assay. 7, 15 The prevalence of HCV infection was reported to be 0.43% in China. However, it was 4.6% in our study. 16 The reason for discrepancy may be due to the case selection bias in the present study. First, the presence of anti-HCV antibody was determined by a doctor. Second, some samples that yielded reactive results in the Architect Anti-HCV assay were selected. Thus, the prevalence of HCV infection should be considered in the evaluation of PPV and NPV according to our study. In summary, the Mindray anti-HCV assay shows a high diagnostic performance, particularly in terms of high sensitivity, excellent specificity, and NPV, in the screening of routine clinical samples. However, our data suggest that each anti-HCV assay has limitations, including the potential for false-positive and false-negative results. Therefore, serum samples that are reactive based on a screening anti-HCV assay should be analyzed with a second test (e.g., HCVcAg, NAT).
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